Related Experiment Videos

Echocardiographic findings in children treated for malignancy with chemotherapy including adriamycin

L Solymar1, I Marky, L Mellander

  • 1Department of Paediatrics I, Gothenburg University, Sweden.

Insights

Adriamycin chemotherapy in children can impair left ventricular function, with 30% showing abnormalities and 45% developing dilated ventricles. Three patients experienced heart failure, highlighting the cardiotoxic potential of this treatment.

Area of Science:

  • Pediatric Oncology
  • Cardiology
  • Cardiotoxicity

Background:

  • Adriamycin (doxorubicin) is a vital chemotherapeutic agent.
  • Chemotherapy, including adriamycin, can pose risks to cardiac function in pediatric patients.
  • Echocardiography is a key tool for assessing cardiac health.

Purpose of the Study:

  • To evaluate the cardiac effects of adriamycin-based chemotherapy in children.
  • To identify echocardiographic indicators of cardiotoxicity in this population.
  • To assess the incidence of left ventricular dysfunction and dilation.

Main Methods:

  • Echocardiography was performed on 37 children undergoing chemotherapy with adriamycin.
  • Systolic time intervals (STI) and left ventricular shortening fraction (delta LVID) were assessed.
  • Cardiac structure and function were analyzed.

Main Results:

  • Abnormal left ventricular function (STI and/or delta LVID) was observed in 30% of patients.
  • 45% of patients exhibited left ventricular dilation, often with thinned walls.
  • Three patients developed congestive heart failure, one with a fatal outcome, linked to adriamycin and chest irradiation.

Conclusions:

  • Adriamycin chemotherapy is associated with significant left ventricular dysfunction and dilation in children.
  • Echocardiographic parameters, particularly delta LVID, are crucial for detecting cardiotoxicity.
  • Close cardiac monitoring is essential for pediatric patients receiving adriamycin, especially with concurrent chest irradiation.

Related Concept Videos